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The incidence of human papilloma virus (HPV)-
associated head and neck squamous cell carci-
noma (HNSCC) is increasing and implicated in
more than 60% of all oropharyngeal carcinomas
(OPSCCs). Although whole-genome, transcriptome,
and proteome analyses have identified altered
signaling pathways in HPV-induced HNSCCs, addi-
tional tools are needed to investigate the unique
pathobiology of OPSCC. Herein, bioinformatics ana-
lyses of human HPV(+) HNSCCs revealed that all tu-
mors express full-length E6 and identified molecular
subtypes based on relative E6 and E7 expression
levels. To recapitulate the levels, stoichiometric ra-
tios, and anatomic location of E6/E7 expression,
we generated a genetically engineered mouse
model whereby balanced expression of E6/E7 is
directed to the oropharyngeal epithelium. The addi-
tion of a mutant PIK3CAE545K allele leads to the
rapid development of pre-malignant lesions marked
by immune cell accumulation, and a subset of these
lesions progress to OPSCC. This mouse provides a1660 Cell Reports 29, 1660–1674, November 12, 2019 ª 2019 The A
This is an open access article under the CC BY-NC-ND license (http://faithful immunocompetent model for testing treat-
ments and investigating mechanisms of immuno-
suppression.INTRODUCTION
Head and neck squamous cell carcinomas (HNSCCs) are the 6th
most common cancer worldwide, with nearly 65,000 people
diagnosed annually in the United States alone (Global Burden
of Disease Cancer Collaboration et al., 2017). Oral cavity squa-
mous cell carcinoma (OSCC), oropharyngeal squamous cell car-
cinoma (OPSCC), and laryngeal squamous cell carcinoma
(LSCC) represent distinct anatomic subsites of HNSCCs that ac-
count for themajority of cases (90%), with the remaining10%
including other locations, such as the thyroid and nasopharynx.
Nearly 50% of HNSCC patients who present with lymph-node-
positive disease (relapsed/metastatic) have a dismal 5-year sur-
vival of <50%, despite current therapeutic strategies that include
radiation, surgery, chemotherapy, and monoclonal antibodies.
Hence, an urgent need exists to better understand the pathobi-
ology of these cancers to facilitate the development of new tar-
geted therapies.
Known risk factors for the development of HNSCC include to-
bacco and alcohol consumption and/or viral infections fromuthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
high-risk human papillomavirus (HPV) (Stein et al., 2014; Suh
et al., 2014). Although carcinogen-induced models exist, human
HNSCCs caused by tobacco and alcohol consumption have
been on the decline in recent decades. In stark contrast, the
global incidence of HPV-associated (HPV(+)) HNSCC is steadily
increasing irrespective of sex and ethnicity and currently ac-
counts for 30%of all HNSCCs but up to 80%of all oropharyngeal
cancers (OPSCCs) (Chaturvedi et al., 2011; D’Souza et al., 2016).
Although the HPV family is comprised of over 120 known geno-
types that can infect the basal layer of mucosal or cutaneous
epithelia in humans (https://pave.niaid.nih.gov) (Bernard et al.,
2010; Van Doorslaer et al., 2017), a subset of six high-risk
HPVs are associated with cancer (Ha and Califano, 2016; Moody
and Laimins, 2010; M€unger et al., 2004). Specifically, HPV16 is
associated with the majority of all HPV(+) cancers, including
90% of head and neck malignancies wherein the expression of
two oncogenes, namely, E6 and E7, is a universal feature (Gilli-
son et al., 2018; Leemans et al., 2018; Cancer Genome Atlas
Network, 2015). Interestingly, HPV16 transcribes E6 and E7 as
a polycistronic pre-mRNA that undergoes posttranscriptional
processing by the host RNA splicing machinery, resulting in mul-
tiple splice isoforms, including the E6*I variant whose accumula-
tion is critical for efficient translation of E7 (Ajiro et al., 2012;
Graham and Faizo, 2017; Tang et al., 2006). Compared to
HPV-negative HNSCCs, HPV(+) cases have distinct molecular
and clinical features, such as age of onset, prognosis, and immu-
nologic profile (D’Souza et al., 2016; Mandal et al., 2016). More
importantly, patients with HPV(+) OPSCC are almost universally
p53 wild type and have superior treatment responses compared
to their generally p53-mutant HPV() OSCC counterparts (Lee-
mans et al., 2018). Consequently, several ongoing clinical trials
are attempting to de-escalate standard therapy for HPV(+)
OPSCC (Blitzer et al., 2014; Gabani et al., 2019) and, yet, few
preclinical genetically engineered mouse models (GEMMs) of
HPV(+) OPSCC exist and none faithfully recapitulate these
unique features.
To address these limitations, we generated and characterized
an inducible GEMM of HPV16-driven oropharyngeal cancer. Our
efforts establish an autochthonous, immunocompetent HPV(+)
GEMM wherein E6 and E7 expression combined with tissue-
specific expression of mutant PIK3CAE545K faithfully phenocop-
ies the histologic and molecular features in developing human
HPV(+) oropharyngeal carcinoma. Consequently, this model
provides a valuable tool for studying the underlying mechanisms
that HPV16-E6/E7 andmutant PIK3CA use to inducemalignancy
and may reveal insights that can lead to new therapies that offer
similar oncologic outcomes to radiation, with less treatment
morbidity. Moreover, these data highlight the strength of our
immunocompetent GEMM for modeling field cancerization and
HPV(+) OPSCC development and progression.
RESULTS
Unspliced E6 and Alternatively Spliced E6*I Transcript
Expression Are Hallmarks of HPV(+) HNSCC
Although several studies have identified E7 as the dominant viral
oncogene responsible for driving HPV-associated tumors, coop-
eration between E7 and E6 is essential for inducing and promot-ing tumorigenesis, respectively (Halbert et al., 1991; Jabbar
et al., 2010; Riley et al., 2003; Strati and Lambert, 2007). Due
to the limited number of nucleotides present between the
HPV16 E6 and E7 open reading frames (ORFs), the accumulation
of alternatively spliced E6*I transcripts is critical for efficient
translation of E7 (Ajiro et al., 2012; Tang et al., 2006). Thus, we
analyzed RNA sequencing (RNA-seq) data from The Cancer
Genome Atlas (TCGA; n = 530) HNSCC Research Network
(https://www.cancer.gov/about-nci/organization/ccg/research/
structural-genomics/tcga) to investigate the relative abundance
of E7 (E6*I) and E6 in HPV(+) HNSCC. An analysis of read align-
ments identified 53 cases with median coverage of >100 for the
total, unspliced HPV16 E6 full-length transcript (Figure S1A). The
apparent decrease in mapped reads between nucleotides 226
and 409 suggested that E6*I, and consequently its translated
product E7, is the predominant variant expressed in HPV(+)
HNSCC, as reported by others (Gillison et al., 2018; Nulton
et al., 2017). However, reads mapping to positions 1–225 and
409–880 represent the sum of E6 and E6*I transcripts. To decon-
volute these transcript variant data and to determine relative E7
versus E6 expression levels, we focused on reads mapping to
splice junctions unique to each transcript variant, summed the
total read counts, and calculated the ratio of spliced/unspliced
(E6*I/E6) transcripts (Figure S1B; Table S1). Remarkably, E6
and the E6*I variant (i.e., E7) are expressed to near equivalent
levels in HPV(+) HNSCC, whereas the alternate E6*II variant
commonly expressed in HPV(+) cervical carcinoma (Pastus-
zak-Lewandoska et al., 2014) is poorly expressed (Figure 1A;
Figures S2A–S2C; Table S1).
To assess if variations in E6/E7 stoichiometry impact host
gene expression, we analyzed mRNA expression of the 53
HPV(+) tumors by ranking the samples as a continuous variable
according to the spliced/unspliced ratio and qualitatively identi-
fied two groups with a ratio cutoff at 2.0 (Figure 1B). The spliced/
unspliced ratio varied from 0.43 to 3.26, with the majority (n = 30)
of cases in group 1 (orange) displaying near equivalent 1:1 ratios
(average [avg] = 1.60) and cases in group 2 (n = 23) displaying
near 2:1 ratios (avg = 2.22) (Figure 1C). Gene set enrichment
analysis (GSEA) revealed that top signatures associated with
these groups include TP53 and E2F1/pRB, targets of E6 and
E7, respectively (Figure 1D; Figure S2D; Tables S2 and S3).
Quantification of E6 and E7 transcript levels within established
HPV16(+) HNSCC cell lines revealed that spliced/unspliced ra-
tios are 1.81- to >3.0-fold higher than the average ratio observed
in group 1 samples and to 1.3- to 2.2-fold higher in group 2 sam-
ples (Figure 1E). Interestingly, western blot analysis confirmed
that E7 levels are much higher than E6 and densitometry mea-
surements revealed that E7/E6 ratios range from 11 to 54, sug-
gesting that modest differences in E7/E6 mRNA expression
levels can have profound effects at the protein level (Figure 1F).
HPV16 E6 and E7 deregulate a host of signaling pathways and
transcription factors by TP53 and E2F1/pRB, respectively, which
target genes involved in cell cycle and proliferation (Figure 1G).
We next tested the consequence of higher E7/E6 ratios and
observed that higher E7 expression correlates with higher
E2F1/pRB target gene expression (Figure 1H). Collectively,
these data indicate that the E7/E6 ratio impacts the pathobiology
of HPV(+) tumors.Cell Reports 29, 1660–1674, November 12, 2019 1661
Figure 1. HPV16 E6:E7 Stoichiometry Im-
pacts Gene Expression in HPV(+) HNSCCs
(A) Raw RNA-seq read counts for full-length, un-
spliced HPV16 E6 and alternatively spliced E6*I
(translated to E7) transcripts.
(B) Heatmap of differentially expressed genes (rows)
ordered using the HPV16 E7/E6 ratio as a contin-
uous variable. Samples (columns, n = 53) are ar-
ranged according to increasing ratio from left to
right.
(C) Spliced to unspliced ratios of HPV16 E7/E6
transcripts plotted against a sorted rank of the ratios
from left to right.
(D) Gene set enrichment analysis (GSEA) of E6/TP53
and E7/E2F1 pathway genes. Separate scores were
calculated for each pathway listed to identify genes
that positively correlate with the E7/E6 ratio versus
genes that negatively correlate with the E7/E6 ratio.
(E) Quantitative real-time PCR analysis of HPV16 E6
and E7 transcript copy numbers calculated using
respective standard curves established with
plasmid DNA encoding E6 and E7. Quantitative real-
time PCR was performed using 10 ng of indicated
cDNA samples as input (n = 3, mean ± SEM). ND,
not detected.
(F) Representative immunoblots of the HPV16 E6
and E7 levels in HPV-positive HNSCC cell lines
relative to control HPV16(+) SiHa and HPV18(+)
HeLa or HPV() HNSCC and normal oral keratino-
cyte (NOK) cell lines. Densitometry quantification
was performed by normalizing the E6 and E7 band
intensities to the actin loading control band intensity
for each respective sample prior to calculating the
E7/E6 ratio.
(G) Schematic of the cell cycle, survival, and differ-
entiation signaling pathways and genes regulated by
high-risk HPV16 oncogenes. E6 targets the tumor
suppressor TP53, whereas E7 targets the tumor
suppressor pRb, relieving E2F1 target gene
repression.
(H) Quantitative real-time PCR analysis of select E7/
E2F1 host pathway genes in HPV-positive HNSCC
cell lines relative to control HPV() NOK cells.
Relative fold expression is shown normalized to
RPL23 mRNA levels (n = 3, mean ± SEM).
Related to Figures S1 and S2 and Tables S1, S2,
and S3.Generation of an Inducible HPV16 Mouse Model with
Balanced E6 and E7 Oncogene Stoichiometry
Previous HPV16-driven GEMMs employed either constiutive or
inducible expression of the E6 and/or E7 oncogenes (Table S4).
However, currently available inducible HPV16 GEMMs were
generated using HPV16 genomic regions that encompass the
E6/E7 ORFs. Unfortunately, E7 expression depends on viral
and host factors that regulate alternative splicing of the E6
transcript, which makes E6 and E7 levels difficult to predict.
To develop a conditional and inducible HPV16 GEMM that re-
capitulates the E6:E7 expression stoichiometry characteristic
of most HPV(+) HNSCCs, we generated knockin transgenic
mice harboring a cassette with the E7 and E6 ORFs separated
by an internal ribosomal entry site (IRES) regulated by a LoxP-
STOP-LoxP element at the constitutively active Rosa26 locus1662 Cell Reports 29, 1660–1674, November 12, 2019(Figure 2A). Mouse embryonic fibroblasts (MEFs) isolated
from Rosa26-LSL-E7iresE6 mice were infected with an adeno-
virus expressing GFP or Cre recombinase (Ad-Cre), leading
to recombination and to the excision of the transcriptional
stop element resulting in the expression of the polycistronic
E7-IRES-E6 message driven by the Rosa26 promoter. The
comparison of E6 and E7 expression levels in heterozygous
(H+/LSL) versus homozygous (HLSL/LSL) MEFs confirmed the
expected increase in expression with near-equivalent E6:E7
stoichiometry, and these RNA levels are reflected in the relative
protein levels (Figures 2B and 2C). Notably, E6:E7 expression
ratios observed in H+/ LSL MEFs are comparable to that seen
in HPV(+) HNSCC. We next analyzed the effects of E6 and
E7 expression on canonical targets downstream of Tp53 and
E2f1/pRb and observed expected changes in the expression
Figure 2. Generation and Characterization of
an Inducible Knockin Mouse Model for
Investigating E6:E7-Driven Oropharyngeal
Tumorigenesis
(A) Schematic depicting the high-risk HPV16
cassette introduced into the Rosa26 locus (left). A
transcriptional STOP element flanked by LoxP sites
is located upstream of the E7 ORF, an internal
ribosomal entry site (IRES), and the E6 ORF
(Rosa26-LSL-E7iresE6). Primary mouse embryonic
fibroblasts (MEFs) transduced with either GFP or
Cre adenoviruses (MOI = 20) were collected 72 h
later and recombination confirmed by PCR-gel
electrophoresis (right).
(B) Quantitative real-time PCR analysis of E6 and E7
transcript copy numbers from heterozygous or ho-
mozygous Rosa26-LSL-E7iresE6 primary MEFs
(H+/LSL orHLSL/LSL) were calculated using respective
standard curves (n = 3, mean ± SEM).
(C) Representative immunoblots of the E6 and E7
levels in H+/LSL or HLSL/LSL MEFs transduced with
either GFP or Cre adenoviruses relative to control
HPV16(+) SiHa and HPV18(+) HeLa cells.
(D) Quantitative real-time PCR analysis of select E6/
Tp53 and E7/E2F1 host pathway genes in H+/LSL or
HLSL/LSL MEFs transduced with either GFP or Cre
adenoviruses. Relative fold expression is shown
normalized to Ubb mRNA levels (n = 3, mean ±
SEM).
Related to Figure S3.profiles of select cell cycle, cell proliferation, DNA replication
and repair, and differentiation (Figure 2D; Figures S3A and
S3B). These data confirm that E6 and E7 are both inducibly ex-
pressed and functional.
Conditional Expression of HPV16 E7iresE6 Disrupts
Epithelial Homeostasis and Promotes Tumorigenesis
To validate the effects of balanced E6 and E7 oncogene expres-
sion in vivo, we spatially targeted the expression of E7-IRES-E6
mRNAs to squamous epithelia lining the oral cavity, pharynx,
esophagus, and forestomach by crossing the Rosa26-LSL-Cell ReporE7iresE6 mice to L2-Cre mice, which ex-
press Cre-recombinase postnatally within
the oro-esophageal epithelia (Nakagawa
et al., 1997; Opitz et al., 2002; Stairs
et al., 2011). The L2-Cre;Rosa26-LSL-
E7iresE6 mice (LH mice) were born with
normal Mendelian distribution but devel-
oped several overt phenotypes, including
hair loss; wrinkling and thickening of the
skin, ears, paws, and muzzle; as well as
occasional ulcerative lesions (Figure 3A;
Figure S4A). Gross macroscopic examina-
tion revealed enlarged oral tissues with
significant changes in oral volume in LH
versus control littermate mice and qRT-
PCR confirmed E6 and E7 expression (Fig-
ures 3B and 3C). Histologic analysis at
8–10 months of age demonstrated fullypenetrant epithelial hyperplasia and mild dysplasia, primarily
within esophageal and cutaneous (face skin) epithelia but with
variable penetrance of mild dysplasia within the tongue (Fig-
ure 3D). Compared to control littermates, LH mice displayed a
significant increase in epithelium thickness but rarely (1 tumor,
n = 16) developed tumors (Figure 3E). Moreover, addition of
the chemical carcinogen 4NQO, frequently used to induce oral
tumors (Vitale-Cross et al., 2009), failed to accelerate or increase
the frequency of oropharyngeal tumor development at low doses
(10 mg/ml) (Figure S4B). Quantification of epithelium thickness
from different anatomic locations of the face skin with or withoutts 29, 1660–1674, November 12, 2019 1663
Figure 3. Conditional Oral-Esophageal Expression of E6 and E7 Induces Hyperplasia and Immune Cell Infiltration
(A) General strategy for generating LHmice by crossing a Cre recombinase strain driven by the Epstein-Barr virus ED-L2 promoter (L) to our knockin HPV16 strain
(H; top). Representative photographs of control littermates and the LH animals at 8–10 months (bottom).
(B) Quantification of oral volume calculated based on the formula for an ellipsoid volume less the oral aperture (n = 3, ***p < 0.0001).
(C) Quantitative real-time PCR analysis of E6 and E7 transcript copy numbers from dissected whole tongue of LH and control littermate mice calculated using
respective standard curves (n = 3, mean ± SEM).
(D) Histologic analysis of epithelial tissues. Representative sagittal sections from adult tongue, esophagus, and cutaneous epithelia were formalin fixed and
embedded, and sections were stained with H&E. Magnification, 2003; bar, 200 mm.
(E) Quantification of cutaneous epithelial thickness calculated in adult LH and control littermate mice (n = 3, ***p < 0.0001).
(legend continued on next page)
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inclusion of the keratin layer did not differ between control and
4NQO-treated animals (Figures S4C and S4D). An analysis of
subcutaneous face skin revealed the striking infiltration of
several different immune cell populations, including polymor-
phonuclear cells (Ly6g+ neutrophils), cytotoxic T cells (Cd8+
T cells), and regulatory T cells (FoxP3+ T cells), supporting the
presence of an immunologic response to viral antigen expres-
sion (Figures 3F–3H; Figure S4E).
To more specifically target progenitor cells within the basal
epithelia, we bred the Rosa26-LSL-E7iresE6 mice to KRT14-
Cre, which is expressed in the basal epithelia as early as E12.
The offspring of these crosses (KH mice) displayed similar overt
phenotypes to the LH mice (Figure 4A). Macroscopic examina-
tion revealed hair loss; wrinkling and thickening of the skin,
ears, paws, and muzzle; but also disruption of hair follicle bulge
stem cells during anagen, as evidenced by patches of new hair
growth, similar to that previously described for HPV16 E6 and
E7 (Michael et al., 2013) (Figure S5A). Similar to LH mice, we
observed significant changes in oral volume in KH versus control
littermate mice and E6 and E7 expression, although transcript
levels were 6- to 7-fold higher in KH epithelia (Figures 4B
and 4C).
Because KRT14 drives Cre expression early in fetal develop-
ment, we next examined the impact of E6:E7 expression on
epithelial proliferation and differentiation in KH mice at select
developmental time points. Compared to control littermates,
KH mice displayed increased suprabasal expression of several
differentiation markers, including keratins (K4 and K10) and in-
volucrin (Ivl), in addition to the cell cycle and proliferation
marker Ccne1, and DNA replication and repair markers Mcm7
and Rrm2 (Figure 4D; Figures S5B and S5C). A significant in-
crease (p < 0.05) in suprabasal mitoses was also observed in
KH mice compared to control littermates (Figures S5B and
S5C). Histologic analysis of adult lingual and cutaneous
epithelia at 1–2 months of age demonstrated fully penetrant
epithelial hyperplasia, dysplasia, and hyperkeratosis in KH ani-
mals compared to control littermates (Figures 4E and 4F). Anal-
ysis of adult (p45) tongues versus embryonic day 16.5 (E16.5)
back skin confirmed induced and sustained expression of E6/
Tp53 and E7/E2f1 pathway target genes in basal epithelia (Fig-
ure 4G; Figure S5D). However, similar to LH mice, KH mice
rarely presented with oral cavity or oropharyngeal tumors
despite frequently developing thymic tumors, as described
with other HPV16 E6/E7 models (Arbeit et al., 1994; Carraresi
et al., 2001) (Figure S5E). Therefore, to assess the effects of
E6:E7 expression on tumorigenesis, we administered a moder-
ate 4NQO dose (20 mg/ml) and observed a significant decrease
(p < 0.05) in oral tumor-free survival for 4NQO-treated KH ani-
mals compared to control littermates (Figure 4H). Collectively,
these data confirm the effects of conditional HPV16 E6 and
E7 on epithelial proliferation and differentiation and validate(F) Histologic and immunohistochemical analysis of immune cell infiltration. Repr
embedded, and H&E stained (top) and reveal morphologic and histologic abnorm
staining is shown for Cd8a+ cytotoxic T cells (middle) and FoxP3+ regulatory T c
(G) Quantification of epidermal versus dermal Cd8a+ cytotoxic T cell infiltration (
(H) Quantification of epidermal versus dermal FoxP3+ regulatory T cell infiltration
Data presented in (B), (E), (G), and (H) are shown as mean ± SEM. Student’s t tethe ability of stoichiometrically balanced E6 and E7 oncogene
expression to drive tumorigenesis in a head and neck carcino-
genesis model.
Intralingual E7iresE6 Activation with Chemical
Carcinogenesis Induces Oropharyngeal Carcinoma
Mounting evidence has supported a role for field cancerization
in the development and progression of HNSCCs (Califano et al.,
1996; Slaughter et al., 1953). Previous efforts to inducibly and
conditionally activate the HPV16 E6/E7 oncogenes in adult
mice used tamoxifen-regulated Cre (CreERtam), but these ubiq-
uitously expressed E6 and E7 within all epithelial tissues (Zhong
et al., 2014). Thus, we sought to develop an autochthonous
method that drives mosaic transgene activation for modeling
field cancerization. We recently reported the creation of biolu-
minescent-fluorescent fusion reporters (LumiFluor) (Schaub
et al., 2015) composed of eGFP and nanoluciferase that pro-
vide enhanced optical properties and signal penetration
through tissues in vivo due to bioluminescence resonance en-
ergy transfer (BRET) (De et al., 2013). Therefore, we generated
a knockin Rosa26-LSL-LumiFluor mouse strain and bred this
animal to KRT14-CreERtam mice to establish iLumiFluor
offspring (Figure 5A). To spatially restrict E6 and E7 expression
at anatomically relevant tissues where HPV-induced HNSCCs
arise, we delivered tamoxifen directly to the tongue to specif-
ically activate the inducible transgenes only within the oropha-
ryngeal regions of the lingual epithelia (Figure 5B). Arbitrary
landmarks separate the divisions of the human pharynx, such
that the oropharynx corresponds to the retromolar trigone pos-
terior to the oral cavity and includes the lateral posterior one-
third of the tongue. However, this does not translate to the
same anatomic region in the mouse due to the elongated
head of rodents and a relatively straight pharynx (Treuting
and Dintzis, 2012). Rather, the posterior two-thirds of the
mouse tongue encompasses the murine equivalent of an
oropharyngeal region and includes intermediate epithelial tran-
sition zones where lesions are known to be manifest in humans.
Different routes of administration (intraperitoneal [i.p.] or intra-
lingual [i.l.]) and varying doses of tamoxifen were evaluated in
a longitudinal manner using non-invasive IVIS bioluminescent
imaging (BLI) over a 3-week time-course (Figure 5C). Non-inva-
sive BLI revealed robust signal detection from oropharyngeal
tissues with as few as two i.l. doses but a significant >100-
fold increase (p = 0.001) with three i.l. doses compared to
five i.p. doses, and these differences were confirmed to arise
from the tongue upon end-point resection. Notably, i.l. tamox-
ifen delivery significantly reduced (>5-fold; p < 0.05) off-target
reporter expression in cutaneous epithelia compared to con-
ventional i.p. administration routes (Figure S6). To assess the
levels and geographic locations of induced transgene expres-
sion, labeled cells were analyzed in frozen sagittal sectionsesentative sagittal sections from adult cutaneous epithelia were formalin fixed,
alities, such as hyperplasia, dysplasia, and pockets of neutrophil infiltrates. IHC
ells (bottom). Magnification, 2003; bar, 200 mm.
n = 3, ***p < 0.0001, **p < 0.001).
(n = 3, ***p < 0.0001).
st (2 tailed) was used to determine significance. Related to Figure S4.
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Figure 4. Conditional Basal Epithelial Expression of E6 and E7 Induces Canonical Tp53/pRb-E2f1 Pathway Genes and Epithelial
Tumorigenesis
(A) General strategy for generating KH mice by crossing a Cre recombinase strain driven by the human keratin 14 (KRT14) promoter (K) to our knockin HPV16
strain (H; top). Representative photographs of control littermates and the KH animals at 1–2 months (bottom).
(B) Quantification of oral volume calculated based on the formula for an ellipsoid volume less the oral aperture (n = 3, mean ± SEM; **p < 0.001).
(C) Quantitative real-time PCR analysis of E6 and E7 transcript copy numbers from dissected whole tongue of KH and control littermate mice calculated using
respective standard curves (n = 3, mean ± SEM).
(D) Immunofluorescence (IF) analysis of neonatal and adult epithelial tissues. Representative sections from neonatal back skin (p0) and adult tongue (p45) were
fixed in paraformaldehyde (PFA) and embedded, and sections were stained for epithelial differentiation markers or E7/ E2F1 targets. White arrowheads denote
suprabasal events. Magnification, 4003; bar, 50 mm.
(E) Histologic analysis of epithelial tissues. Representative sagittal sections from adult tongue and cutaneous epithelia were formalin fixed and embedded, and
sections were H&E stained. Magnification, 2003; bar, 200 mm.
(F) Quantification of cutaneous epithelial thickness calculated in adult KH and control littermate mice (n = 3, ***p < 0.0001).
(G) Quantitative real-time PCR analysis of select E6/Tp53 and E7/E2F1 host pathway genes in adult KH and control littermate mice. Relative fold expression is
shown normalized to Ppib mRNA levels (n = 3, mean ± SEM).
(H) Epithelial E6 and E7 expression together with 4NQO treatment increases oral tumor development. Kaplan-Meier analysis of KH and control littermate mice
provided with 4NQO (20 mg/ml) in the drinking water for 8 weeks followed by weekly oral cavity examination for gross pathologic changes. Tumor onset was
significantly reduced (p = 0.0499) for KH mice (median tumor-free survival = 123 days) compared to control littermates.
Data presented in (B) and (F) are shown as mean ± SEM. Student’s t test (2 tailed) was used to determine significance. Related to Figure S5.taken from tongues resected at end-point (Figure 5D). Patches
of LumiFluor-labeled cells (GFP+) were observed throughout
the basal epithelial layers of the dorsal, ventral, and base of
tongue, establishing that i.l. tamoxifen delivery provides a
robust and reproducible method for inducing mosaic transgene
expression within lingual epithelia and supporting the utility of
this methodology for modeling field cancerization.
Next, we generated mice that enable conditional and induc-
ible E7iresE6 expression within tongues of adult animals by1666 Cell Reports 29, 1660–1674, November 12, 2019breeding KRT14-CreERtam and Rosa26-LSL-E7iresE6 mice.
As expected, the offspring of these crosses (iKH mice) dis-
played no overt phenotypes in the absence of tamoxifen (Fig-
ures 6A and 6B). Notably, in stark contrast to LH and KH
mice, there is a significant reduction in the oral volumes of i.l.
tamoxifen-treated iKH animals, indicating that i.l. tamoxifen de-
livery minimizes expression in off-target tissues despite robust
lingual E6 and E7 expression (Figures 6C and 6D). To assess if
direct injection of tamoxifen into the tongues has any adverse
Figure 5. Generation and Application of Inducible Reporter Knockin Mice (iLumiFluor) for Developing Methods to Target Lingual and
Oropharyngeal Epithelia
(A) General strategy for testing the efficacy of intralingual (i.l.) tamoxifen (TAM) administration to activate the estrogen receptor Cre recombinase fusion (KRT14-
CreERtam) and induce eGFP-NanoLuc (GpNLuc LumiFluor) transgene expression within the tongue following Cre-mediated recombination and excision of the
STOP cassette.
(B) Schematic of transverse and sagittal views highlighting key lingual anatomic features including the oropharynx, dorsal tongue, and ventral tongue. TAM was
delivered by i.l. injection to the posterior, dorsal-lateral tongue to minimize dorsal tongue swelling and disruption to eating or drinking.
(C) Targeted induction of bioluminescent signal in adult tongues. Bioluminescent imaging (BLI) of iLumiFluor and control littermate mice injected either 23 or
33 i.l. versus 53 i.p. with TAM. Live animal, non-invasive BLI was performed temporally and signal levels graphed relative to baseline. Representative images for
both live, non-invasive BLI and end-point resected tongues 16 days post-TAM are presented (n = 3, ***p < 0.0001).
(D) Immunofluorescence analysis reveals mosaic reporter expression throughout the adult tongue. Representative sections of adult tongues fixed in para-
formaldehyde (PFA) and embedded, and sections were stained for epithelial basement membrane (Integrin-b4; red), LumiFluor (eGFP; green), and nuclei (DAPI;
blue). Tile scan of 33 i.l. TAM (top). Comparison of TAM treatment regimen effects at various anatomic locations in iLumiFluor and control littermate mice
(bottom). Tile scan of magnification at 203 with 1.25 optical zoom.
Data presented in (C) is shown asmean ±SEMof a representative experiment (n = 3 experiments). Two-way ANOVAwith Bonferroni’s post hoc tests were used to
determine significance. Related to Figure S6.effects on feeding behaviors, we closely monitored animals
over the course of 5 months and found no significant change
in body weight for male or female animals (Figure 6E). Histo-
logic analysis at 8–10 months of age demonstrated fully pene-
trant lingual hyperplasia and dysplasia but a significant reduc-
tion in cutaneous (face skin) epithelial thickness compared to
LH and KH mice (Figures 6F and 6G). Moreover, iKH mice dis-
played increased lingual expression of the E7/E2f1-regulated
target Mcm7 within the suprabasal layers compared to controllittermates (Figure 6H). Notably, the addition of 4NQO to iKH
mice promoted the development of oropharyngeal squamous
cell carcinomas (Figure 6I; Figure S7A). Histologic and immuno-
histochemical (IHC) analysis of tongue sections confirmed
recruitment of immune infiltrates, including neutrophils, cyto-
toxic T cells, and regulatory T cells (Figure 6J; Figure S7A).
Collectively, these data validate the utility of this method for
generating an autochthonous model of HPV16-associated
oropharyngeal tumorigenesis.Cell Reports 29, 1660–1674, November 12, 2019 1667
Figure 6. Targeted E6 and E7 Expression Induces Hyperplasia and Dysplasia with Reduced Off-Target Effects
(A) General strategy for generating conditional and inducible iKH mice by crossing the KRT14-CreERtam (iK) strain to our knockin HPV16 strain (H).
(B) Representative photographs of iKH animals at 8–10 months.
(legend continued on next page)
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Autochthonous HPV16 E7iresE6 and PIK3CAE545K
Expression Induces Oropharyngeal Carcinoma
HPV(+) HNSCC in humans is characterized by low relative muta-
tional burden, suggesting that few genomic alterations are
required in combination with HPV16 E6 and E7 oncogene
expression to drive tumorigenesis (Leemans et al., 2018; Cancer
Genome Atlas Network, 2015). Indeed, integrated bioinformatics
analyses revealed that of the downstream pathways activated in
HNSCC, PIK3CA alterations are by far among the dominant
driver events, where nearly 40% of all HPV(+) HNSCC cases har-
bor gain-of-function PIK3CA mutations at two key hotspots
within the helical domain, namely, E542K and E545K (Hayes
et al., 2015; Ng et al., 2018).
To recapitulate this HNSCC PIK3CA alteration, we generated a
GEMM that combinesRosa26-LSL-E7iresE6 andmutant PIK3CA
(Rosa26-LSL-PIK3CAE545K) (Meyer et al., 2013) under the control
of KRT14-CreERtam. Offspring of these crosses (iKHPmice) were
bornwith normalMendelian distribution, but excitingly, restricting
post-natal activation of these transgenes by using our i.l. tamox-
ifen delivery method induced the rapid development of oropha-
ryngeal tumors (Figure 7A). Interestingly, macroscopic examina-
tion revealed that multifocal premalignant lesions develop with
100% penetrance and moderate burden (2–5 lesions/tongue)
during a short (4–6 week) time period post-tamoxifen and that,
of these lesions, oropharyngeal tumors develop with 40%
penetrance (1–2 tumors/tongue) starting as early as 6–8 weeks
post-tamoxifen (Figure 7B; Table S5). These tumors primarily
developed within the posterior two-thirds of the mouse tongue
that represent the murine oropharynx equivalent at the dorsal-
lateral borders and the base-of-tongue, although occasional
ventral tumors also developed. Histologic and immunohisto-
chemical analysis confirmed the presence of epithelial hyperpla-
sia and moderate-to-severe dysplasia in the pre-malignant le-
sions and that some of these lesions progress to oropharyngeal
squamous cell carcinoma (Figures 7B and 7C). Moreover, these
analyses confirmed that although the majority of these oral tu-
mors are moderately differentiated carcinoma in situ that display(C) Comparison of oral volume fold change between LH, KH, and iKH and con
expression to the lingual and oropharyngeal epithelia significantly reduces off-ta
(D) Quantitative real-time PCR analysis of E6 and E7 transcript copy numbers fro
respective standard curves (n = 3, **p < 0.001, ***p < 0.0001).
(E) Body weight remains unchanged with lingual TAM administration. Compariso
significant acute or long-term impact of i.l. TAM delivery either during or following
tamoxifen injection time frame. Blue shading highlights daily animal monitoring pe
health assessment.
(F) Histologic analysis of epithelial tissues. Representative sagittal sections from a
stained. Black arrowheads denote suprabasal mitoses. Magnification, 4003; ba
(G) Comparison of cutaneous epithelial thickness fold change between LH, KH,
lingual epithelia significantly reduces general cutaneous epithelial manifestations
(H) Increased expression of a E7/E2F1 target within iKH tongues. IF analysis of re
MCM7. White arrowheads denote suprabasal events. Magnification, 4003; bar,
(I) Targeted expression of E6 and E7 together with 4NQO treatment drives orop
animal experiment (top) and representative images of the gross morphology for tu
the drinking water (bottom). Dotted lines delineate the tumor boundary.
(J) Histologic and immunohistochemical analysis of immune cell infiltration. Rep
tongues (left) and reveal morphologic and histologic abnormalities consistent w
invasive epithelial island (yellow arrowhead). IHC staining of infiltrating Cd8a+ cy
Data presented in (C), (D), and (G) are shown as mean ± SEM of a representative
tests were used to determine significance. Related to Figure S7.a largely exophytic, papillary appearance (Figure S7B), some are
ulcerative and display invasive features with basement mem-
brane disruption and muscle invasion accompanied by poorly
differentiated areas characteristic of HPV(+) HNSCC (Figure 7B).
Similar to the oropharyngeal tumors that arise in the iKH mice
with combined chemical carcinogenesis (Figures 6I and 6J),
iKHP oropharyngeal tumors displayed significant leukocyte infil-
tration (Figure 7C). Notably, this immune cell recruitment is an
early feature in disease progression, as these infiltrating cells
are also present in pre-malignant lesions (Figure S7D). Previous
work demonstrated that this enhanced leukocyte infiltration is
associated with PIK3CA activation and that HPV(+) HNSCCs
harboring PIK3CA mutations are associated with activation of
mTOR but not of AKT, suggesting that E6 and E7 expression in-
hibits the ability of wild-type and/or mutant PIK3CA to activate
AKT (Du et al., 2016). To investigate these mechanisms, we
next examined S6 and Akt activation by immunohistochemistry
and compared to control littermate tongues. We confirmed
robust S6 phosphorylation at Ser235/236 in the iKHP oropharyn-
geal tumors but did not detect significant differences in AKT
phosphorylation at Ser473 between control oral tissues and
GEMM tumors (Figure 7D). Furthermore, similar to previous
observations (Aguilar-Martinez et al., 2015; Rong et al., 2019;
Sewell et al., 2014), we also found that these tumors exhibit
low-level ERK1/2 activation (Thr202/Tyr204 phosphorylation)
despite robust suprabasal total ERK1/2 expression (Figure S7E).
Collectively, these data indicate that mTOR activation contrib-
utes to tumor progression in our HNSCCGEMM and that mutant
PIK3CA in combination with balanced expression of HPV E6 and
E7 is sufficient to drive oral tumorigenesis.
DISCUSSION
HPV is the most common sexually transmitted infection in the
United States (Satterwhite et al., 2013), with over 20 million
active cases and an estimated 6 million new cases each year ac-
cording to the Centers for Disease Control and Prevention. Thistrol littermate mice 42 weeks post-tamoxifen injection reveals that restricting
rget effects on external oral epithelial volume (n = 3, *p < 0.01).
m dissected whole tongue of iKH and control littermate mice calculated using
n of male versus female body weights over the course of the study reveals no
administration, respectively (n = 3–8, mean ± SEM). Yellow shading highlights
rformed immediately post-injection followed thereafter by periodic weight and
dult tongue and cutaneous epithelia were formalin fixed, embedded, and H&E
r, 50 mm.
and iKH and control littermate mice reveals that restricting expression to the
(n = 3, mean ± SEM; **p < 0.001, *p < 0.01).
presentative sections from adult iKH tongues stained for the HPV16 biomarker
50 mm.
haryngeal squamous cell carcinoma development. Schematic overview of the
mors (yellow arrow) that develop in the iKHP mice provided 4NQO (20 mg/ml) in
resentative sections from formalin-fixed, embedded, and H&E-stained iKHP
ith oropharyngeal squamous cell carcinoma. Inset highlights a region with an
totoxic T cells (right). Magnification, 2003; bar, 200 mm.
experiment (n = 3 experiments). Two-way ANOVA with Bonferroni’s post hoc
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Figure 7. Autochthonous HPV16 E6 and E7 Coupled with PIK3CAE545K Expression Induces Preneoplastic Lesions That Rapidly Progress to
Squamous Cell Carcinoma
(A) General strategy for generating conditional and inducible iKHP mice by crossing the iKH strain to an inducible PIK3CAE545K strain (P). Representative pho-
tographs of independent tumors from iKHP animals at 8 weeks.
(B) Mutant PIK3CA cooperates with HPV16 E6 and E7 oncogenes to drive tumorigenesis. Representative images of the gross morphology for control and iKHP
tongues at various times post-tamoxifen (left). Representative H&E-stained sections of control tongues compared to iKHP tongues harboring early, pre-malignant
lesions (4–6 weeks) or tumors (6–8 weeks; middle). Representative invasive squamous cancer displaying both papillary, exophytic growth, and ulcerative lesion
with basement membrane disruption, muscle invasion, and poorly differentiated areas. Tumor inset highlights invasive features (right, 2003) with mitotic figures,
nuclear pleomorphism, and hyperchromatism (yellow arrowheads) and keratin pearls (black arrowheads). Magnification (left), 403; bar, 200 mm.
(C) Quantification of epidermal versus dermal Cd8a+ cytotoxic T cell infiltration (left) or FoxP3+ regulatory T cell infiltration (right) in control versus pre-malignant
lesions or frank tumors (n = 3, mean ± SEM; ***p < 0.0001, **p < 0.001, *p < 0.01).
(D) IHC staining of Ki67 demonstrating increased suprabasal proliferation of tumors (left) accompanied bymarked increases in p-S6Ser235/236 (middle) staining but
not pAKTSer473 (right). Magnification, 2003; bar, 200 mm.
Data presented in (C) is shown as mean ± SEM. Student’s t test (2 tailed) compared to control was used to determine significance. Related to Figure S7.rising HPV epidemic poses significant health risks due to the
causal role that HPV plays in the development of several can-
cers, including a distinct anatomic subset of head and neck can-
cers (OPSCCs) (Ha and Califano, 2016; Moody and Laimins,
2010; M€unger et al., 2004). In fact, there is a rising incidence of
HPV(+) HNSCCs linked to changes in sexual behaviors that pro-
mote viral transmission and oral infection (Chaturvedi et al.,
2011; Gillison et al., 2008; Stein et al., 2014), but the cooperating
genetic insults that drive development and progression of this
cancer remain poorly understood.
Several in vitro and in vivo model systems exist for investi-
gating HPV-associated pathogenesis (Doorbar, 2016; Lambert,
2016; Spiotto et al., 2013), but the currently available GEMMs
each have a unique set of limitations that must be considered
when designing studies (Table S4). These HPV GEMM models
fall into two broad categories, namely, those that display consti-1670 Cell Reports 29, 1660–1674, November 12, 2019tutive versus those with inducible HPV16 E6 and/or E7 oncogene
expression. Constitutive GEMMs for in vivo study include the aA-
HPV16-E6/E7 (Griep et al., 1993; Lambert et al., 1993), K14-
HPV16 (Arbeit et al., 1994), K14HPV16E6 (Song et al., 1999),
and K14HPV16E7 (Herber et al., 1996) transgenic mouse
models, where HPV16 genes are expressed by the aA crystallin
or keratin 14 (K14) promoters. Studies using aA-HPV16-E6/E7
transgenic mice revealed that the aA crystallin promoter suc-
cessfully directs E6/E7 expression to the mouse ocular lens,
but this model is confounded by non-specific expression within
cutaneous epithelia, limiting the ability to model HPV-induced
oropharyngeal, cervical, or anogenital cancers (Griep et al.,
1993). Consequently, subsequent studies used a basal epithe-
lial-cell-specific keratin promoter (K14) to direct oncogene
expression to cutaneous and mucosal epithelia, but these
models have low tumor penetrance and the K14 promoter is
activated early in embryogenesis by E12.5 such that constitutive
in utero oncogene expression impacts normal epithelial develop-
ment and viral antigens induce immune tolerance, minimizing
usefulness as an immunocompetent model (Doan et al., 1999;
Melero et al., 1997).
To generate systems that model the onset of HPV infection in
adult humans, two inducible transgenic models were recently
generated that enable conditional basal epithelial-cell-specific
and tamoxifen- (Zhong et al., 2014) or doxycycline- (Callejas-Va-
lera et al., 2016) inducible expression (K14-CreERTam or K5-rtTA,
respectively). However, both models are transgenic (and thus
subject to founder effects linked to sites of transgene integration)
and require high doses of tamoxifen (100 mg; 20 mg/ml for
5 days) or doxycycline (6 g/kg chow). Moreover, E6 and E7 pro-
mote cancer by distinct mechanisms that disrupt cellular prolifer-
ation (E7/E2F1) and apoptotic (E6/TP53) programs while also
promoting genomic instability and immune cell invasion (Moody
and Laimins, 2010; M€unger et al., 2004; Rautava and Syrjänen,
2012). Unfortunately, both models use the E6/E7 ORF amplified
from the HPV viral genome and lack proper control of E7 expres-
sion, which is dependent on several variables, including host fac-
tors that regulate cellular differentiation, EGFR-ERK1/2 signaling,
and, most importantly, mRNA splicing (Graham and Faizo, 2017;
McFarlane et al., 2015; Rosenberger et al., 2010; Wu et al., 2017).
Due to a limited number of nucleotides located between the E6
and E7 ORFs, splicing of the polycistronic E6 mRNA transcript
into the E6*I variant is necessary to relieve spacing constraints
imposed on the ribosome and enhance E7 translation efficiency
(Ajiro et al., 2012; Tang et al., 2006). Notably, E7 expression levels
are either not reported (Zhong et al., 2014) or ratios appear to be
lower than E6 based on available western blot data (Callejas-Va-
lera et al., 2016), suggesting that these models may suffer from
inadequate E7 expression that do not faithfully recapitulate the
combined effects of E6 and E7 oncogene actions on TP53 and
RB, respectively, in promoting HPV(+) oropharyngeal tumorigen-
esis. In fact, studies have identified HPV16 E7 as the dominant
oncogene with respect to promoting cancer development
(Halbert et al., 1991; Riley et al., 2003; Strati and Lambert,
2007), and repression of E7 provokes regression of high-grade
cervical dysplasia and cervical tumors irrespective of E6 expres-
sion (Jabbar et al., 2009, 2012). Importantly, mice that express
both the E6 and E7 transgenes display an increased incidence
of invasive carcinomas (Jabbar et al., 2010), further supporting
the need for GEMMs that accurately reflect the stoichiometry
driving this pathobiology.
We developed a knockin GEMM of HPV(+) HNSCC whose
autochthonous disease progression reflects the histopatholog-
ical and molecular features observed in human HPV(+) OPSCC
Our approach (Rosa26-loxP-STOP-loxP-E7iresE6; ‘‘H’’ mice)
spatiotemporally restricts expression of the high-risk HPV16 E6
and E7 oncogenes to the oropharyngeal basal epithelium in
post-natal immunocompetent mice. This approach recapitulates
the in vivoE6/E7 expression levels and stoichiometric ratios seen
in human HPV(+) HNSCC tumors and HPV(+) HNSCC cell lines.
Although some challenges still exist in modeling human biology
in a rodent, this is an unfortunate limitation of many animal
models. We confirmed that autochthonous mosaic transgene
expression is achievable within relevant oropharyngeal sites ofHPV infection by using an i.l. targeting methodology coupled
with a second knockin GEMM we generated using our recently
described bioluminescent-fluorescent LumiFluor optical re-
porter tool (Rosa26-loxP-STOP-loxP-LumiFluor). Therefore, this
method also provides a tractable approach to modeling field
cancerization in GEMMs.
Two recent genomics studies reported that the alternatively
spliced E6*I transcript is the dominant variant expressed in
HPV(+) tumors and that full-length E6 transcripts are present at
substantially lower levels (Gillison et al., 2018; Nulton et al.,
2017). Consequently, these observations further limit the utility
of current inducible HPV GEMMs because full-length E6 tran-
scripts rather than E6*I predominate in those models, so the
impacts of E7 are minimal. In stark contrast, we discovered that
full-length E6 and E6*I transcripts are expressed to near equiva-
lent levels inmost human primaryHPV(+) HNSCCs. The observed
difference in our results can be accounted for by the bioinformat-
ics approaches we used. Specifically, there is an apparent
decrease in overall reads mapping to the alternatively spliced re-
gion missing from the E6*I transcript when viewing read pileup
data (nt 226 – 409), but reads mapping 50 or 30 to this region actu-
ally represent reads that can arise from shared sequences com-
mon to both full-length E6 and spliced E6*I transcripts. Therefore,
we addressed this caveat by only considering junction-spanning
reads unique to each splice variant. Furthermore, relative E6:E7
ratios correlate with distinct molecular subtypes and available
HPV(+) HNSCC cell lines express increased E7 levels marked
by increased E7/E2F1-regulated target gene expression, such
as the canonical HPV biomarker MCM7 (Strati et al., 2006). This
feature may be due to the loss of selective pressures required
to maintain E6 expression following TP53 deletion or mutation
that occurred during the establishment of these cell lines. Thus,
currently available HPV(+) cell lines may best model only a small
subset of HPV(+) HNSCC cases where high E7 expression is
coupled with alternative mechanisms of TP53 pathway inhibition.
Our HPV16 GEMM allows one to define the genetic events
that drive multi-stage tumorigenesis. Interestingly, post-natal
induction of these HPV oncogenes within lingual epithelia of
our GEMM circumvents the immune tolerance phenotypes
that plague constitutive model systems (Doan et al., 1999; Me-
lero et al., 1997). This is reflected by the robust leukocyte infil-
tration we observe in early pre-malignant lesions and tumors
that develop in our GEMM, suggesting that this model pre-
serves the immune system’s ability to respond to exogenous
viral antigen exposure. These findings have important applica-
tions and support the use of our HPV16 GEMM as an immuno-
competent preclinical platform for investigating mechanisms of
immunosuppression in HPV(+) HNSCC. A limitation of our cur-
rent HPV GEMM mice is that oropharyngeal tumors that
develop are primarily carcinoma in situ with only occasional
poorly differentiated invasive features, suggesting that addi-
tional genetic alteration(s) are required for their progression.
However, the spontaneous and incomplete conversion of all
pre-malignant lesions to HNSCC also presents an intriguing
opportunity to evaluate the utility of this model for investigating
those molecular events responsible for the progression of only
a subset of lesions to malignancy. Although previous models
of oral tumorigenesis expressed CCND1, mutant Kras, Tp53,Cell Reports 29, 1660–1674, November 12, 2019 1671
Tgfbr1, or Notch1 (Spiotto et al., 2013), we specifically chose to
investigate the contribution of mutant PIK3CA in promoting the
development of HNSCCs given accumulating genomic
sequencing evidence pointing to a potential role for PIK3CA
amplification and/or mutation as a key driver event (Gillison
et al., 2018; Hayes et al., 2015; Leemans et al., 2018; Cancer
Genome Atlas Network, 2015). Aberrant PI3K signaling en-
hances tumorigenic potential by increasing cell proliferation
and survival and promoting migration, invasion, metabolism,
angiogenesis, as well as resistance to chemotherapy (Hafsi
et al., 2012; Wong et al., 2010; Yuan and Cantley, 2008).
Most gain-of-function PIK3CA mutations occur in either the ki-
nase (H1047R) or helical domains (E542K and E545K) of p110a
and create a constitutively active enzyme (Samuels et al.,
2004). But unlike breast carcinoma and HPV() HNSCC, nearly
all HPV(+) HNSCCs selectively accumulate mutations within the
helical domain, consistent with mRNA editing induced by
APOBEC-mediated cytosine deaminase mutagenesis (Hayes
et al., 2015; Ng et al., 2018). Indeed, deregulation of pathways
that converge on mTOR signaling are characteristic of human
HPV(+) HNSCC, and activation of this pathway also occurs in
mouse models of HPV-associated cervical and oropharyngeal
cancers (Callejas-Valera et al., 2016). Thus, our findings
demonstrating selective activation of mTOR rather than AKT
signaling are aligned with observations made in both human
HPV(+) HNSCC and mouse models of these cancers. Future
studies aimed at defining the genetic events that cooperate
with E6/E7;PIK3CAE545K to promote invasion and migration
will be important to understand the mechanisms that underlie
HPV(+) cases with poor prognosis.
Collectively, we demonstrate that significant similarities exist
between human HPV(+) HNSCC and our HPV GEMM, establish-
ing this model system as a powerful platform for gaining new
insights into the underlying molecular mechanisms governing
HPV(+) HNSCC development and progression and investigating
the efficacy of currently available and next-generation therapies.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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Ramsey (Harvard University, Boston, MA)
RRID: CVCL_L227
Human: OKF4-E6/E7 cell line Gift from Jim Rheinwald and Matthew
Ramsey (Harvard University, Boston, MA)
RRID: CVCL_L226
Human: OKF6-TERT1 cell line Gift from Jim Rheinwald and Matthew
Ramsey (Harvard University, Boston, MA)
RRID: CVCL_L224
Human: OKF6-E6/E7 cell line Gift from Jim Rheinwald and Matthew
Ramsey (Harvard University, Boston, MA)
RRID: CVCL_L223
Human: GMSM-K cell line Gift from Valerie Murrah (UNC-Chapel
Hill, NC)
RRID: CVCL_6A82
Human: UM-SCC-74A HPV-negative HNSCC
cell line
Gift from Thomas Carey (University of
Michigan (Ann Arbor, MI)
RRID: CVCL_7779
Human: UM-SCC-5 HPV-negative HNSCC cell line Gift from Thomas Carey (University of
Michigan (Ann Arbor, MI)
RRID: CVCL_7762
Human: UM-SCC-11A HPV-negative HNSCC cell line Gift from Thomas Carey (University of
Michigan (Ann Arbor, MI)
RRID: CVCL_7715
Human: UM-SCC-14A HPV-negative HNSCC cell line Gift from Thomas Carey (University of
Michigan (Ann Arbor, MI)
RRID: CVCL_7719
Human: SCC15 HPV-negative HNSCC cell line Gift from Ben Major (UNC-Chapel Hill, NC) RRID: CVCL_1681
Human: SCC25 HPV-negative HNSCC cell line Gift from Ben Major, (UNC-Chapel Hill, NC) RRID: CVCL_1682
Human: UM-SCC-47 HPV-positive HNSCC cell line A gift from Randall Kimple (University of
Wisconsin, Madison, WI)
RRID: CVCL_7759
Human: 93-VU147T HPV-positive HNSCC cell line A gift from Randall Kimple (University of
Wisconsin, Madison, WI)
VU-SCC-147; RRID:CVCL_L895
Human: UD-SCC-2 HPV-positive HNSCC cell line A gift from Randall Kimple (University of
Wisconsin, Madison, WI)
RRID: CVCL_E325
Human: UPCI:SCC090 HPV-positive HNSCC cell line A gift from Randall Kimple (University of
Wisconsin, Madison, WI)
RRID: CVCL_7794
(Continued on next page)
e2 Cell Reports 29, 1660–1674.e1–e7, November 12, 2019
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Experimental Models: Organisms/Strains
Mouse: Rosa26-LSL-E7iresE6: Albino B6(Cg)-
Tyrc-2J/J Male and Female mice were used for
experiments, and randomly assigned to
experimental groups.
This paper N/A
Mouse: Rosa26-LSL-GpNLuc: Albino B6(Cg)-
Tyrc-2J/J Male and Female mice were used for
experiments, and randomly assigned to
experimental groups.
This paper N/A
Mouse: Albino B6(Cg)-Tyrc-2J/J Male and
Female mice used for breeding.
Jackson Laboratory Stock# 000058
Mouse: C57BL/6J Male and Female mice used
for breeding.
Jackson Laboratory Stock# 000664
Mouse: Rosa26-LSL-PIK3CAE545K: Albino B6(Cg)-
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experimental groups.
Meyer et al., 2013; a gift from Mohammed
Bentires-Alj (University of Basel, Basel,
Switzerland) and backcrossed in
this paper
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Mouse: L2-Cre: Albino B6(Cg)-Tyrc-2J/J Male
and Female mice were used for experiments,
and randomly assigned to experimental
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Stairs et al., 2011; a gift from Anil Rustgi
(University of Pennsylvania, Philadelphia,
PA) and backcrossed in this paper
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Mouse: KRT14-Cre: C57BL/6J Male and
Female mice were used for experiments,
and randomly assigned to experimental
groups.
A gift from Elaine Fuchs (The Rockefeller
University, New York City, NY)
N/A
Mouse: KRT14-Cretam: Albino B6(Cg)-Tyrc-2J/J
Male and Female mice were used for experiments,
and randomly assigned to experimental groups.




Primers for gene expression analysis, see Table S7 This paper N/A
Primers for Genotyping animal models, see Table S7 This Paper N/A
Primers used to verify DNA Recombination,
see Table S7
Forward Primer: from this paper Reverse
Primer: Zhong et al., 2014
N/A
Recombinant DNA
pBigT Addgene; Srinivas et al., 2001 Plasmid# 21270
pRosa26-PA Addgene; Srinivas et al., 2001 Plasmid# 21271
MIGR1 Addgene; Pear et. al., 1998 Plasmid# 27490
pRetroX-Tight_MCS_PGK-GpNLuc Addgene; Schaub et al., 2015 Plasmid# 70185
Software and Algorithms




DESeq2 Love et al., 2014 N/A
STAR v2.4.2a Dobin et al., 2013 N/A
R (version 3.1.2) https://www.r-project.org/ N/A
ImageJ Schneider et al., 2012 https://imagej.nih.gov/ij/
GraphPad Prism 6 N/A https://www.graphpad.com
LAS AF Software Leica https://www.leica-microsystems.
com/products/microscope-
software/p/leica-las-x-ls/
Cell Reports 29, 1660–1674.e1–e7, November 12, 2019 e3
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the LeadContact, Antonio L.
Amelio (antonio_amelio@unc.edu). The plasmids, mouse lines, and cell lines generated in this study are available upon request via a
material transfer agreement (MTA).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse Models
All animal studies were reviewed and approved by The University of North Carolina at Chapel Hill Institutional Animal Care and Use
Committee. The Rosa26-LSL-E7iresE6mice were generated by knocking-in a polycistronic cassette containing the high risk HPV16
E7 and E6 cDNAs separated by an IRES element into a Rosa26-loxP-Stop-loxP cassette, using the pBigT and pRosa26-PA vectors,
as previously described (Srinivas et al., 2001). Briefly, the E7 cDNA was cloned into pBigT via XhoI and NotI while the E6 cDNA was
cloned into the MIGR1 plasmid downstream of the IRES element via NcoI and SalI. An IRES-E6 amplicon containing NotI and SacI
sites was then subcloned into the pBigT-E7 construct to create pBigT-E7iresE6 prior to shuttling into the Rosa26-PA destination vec-
tor via Pac1 and AscI. Similarly, Rosa26-LSL-GpNLuc mice were generated by knocking-in the GpNLuc (Schaub et al., 2015)
LumiFluor optical reporter cDNA into a Rosa26-loxP-Stop-loxP cassette by first subcloning GpNLuc into pBigT prior to
shuttling into the Rosa26-PA destination vector. MEFs from founder lines were screened by transducing cells with Adeno-Cre virus
(MOI = 20) and analyzing the recombined allele from the Rosa26-LSL-GpNLuc mice by measuring bioluminescent light output or by
PCR and western blot for the Rosa26-LSL-E7iresE6 mice. The L2-Cre (Stairs et al., 2011) (a gift from Anil Rustgi, University of Penn-
sylvania, Philadelphia, PA), KRT14-Cre (a gift from Elaine Fuchs, The Rockefeller University, New York City, NY), and KRT14-Cretam
(The Jackson Laboratory, Stock #: 005107) Cre recombinase strains were crossed to the Rosa26-LSL-E7iresE6mice to generate the
LH, KH, or iKH models, respectively. The iKH mice were crossed to Rosa26-LSL-PIK3CAE545K (a gift from Mohamed Bentires-Alj,
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland) (Meyer et al., 2013) to generate the oropharyngeal cancer
GEMM (iKHP). The KRT14-Cretam mouse was crossed with Rosa26-LSL-GpNLuc to generate the iLumiFluor reporter model. All an-
imals were backcrossed to C57BL/6J or albino B6(Cg)-Tyrc-2J/J mice (The Jackson Laboratory, Stock #: 000664 or Stock #: 000058)
for seven to ten generations.
To induce Cre-mediated transgene recombination in the tongues of iLumiFluor, iKH, or iKHP mice, tamoxifen was administered to
the lingual submucosa by direct injection. Optical reporter signal or tumor development were regularly monitored by IVIS BLI imaging
and/or oral examination, respectively. Male and female mice were used for experiments, and randomly assigned to experimental
groups. Mice were sacrificed for the humane endpoints as follows. For the autochthonous mouse models, mice were sacrificed
for weight loss more than 20% of the initial animal weight or tumor size volume of > 40 mm3 as evaluated by caliper and/or BLI mea-
sure. In our studies, all micewere sacrificed because of tumor size. The endpoint for allograft models was tumor volume > 500mm3 or
weight loss greater than 20% body weight.
Cell lines
Mouse embryonic fibroblasts (MEFs) were prepared as previously described and cultured in DMEM (GIBCO, cat. #: 11965-092) sup-
plemented with 10% FBS (Atlanta Biologicals, cat. #: S11550), 1x penicillin, streptomycin, glutamine (1xPSG - GIBCO, cat. #:
10378016,) 1x GlutaMAX (GIBCO, cat. #: 35050-061), and 0.1mM b-Mercaptoethanol (Fisher Chemicals, cat. #: 034462). ‘Normal’
oral keratinocyte (NOK) cell lines OKF4-TERT1, OKF4-E6/E7, OKF6-TERT1, and OKF6-E6/E7 (a gift from Jim Rheinwald and
Matthew Ramsey, Harvard University, Boston, MA) and the GMSM-K (Gilchrist et al., 2000) (a gift from Valerie Murrah, UNC-Chapel
Hill, Chapel Hill, NC) were grown in keratinocyte serum free media (KSFM) from (GIBCO, cat. #: 17004-042). The OKF6/OKF4 lines
were grown in KSFMmedia supplemented with 25 mg of bovine pituitary gland extract (BPE), 0.2 ng/ml of EGF, 300mMof CaCl2, and
1x of PSG (Dickson et al., 2000; Schön and Rheinwald, 1996). The GMSMK cells were cultured in KSFM supplemented with 50mg/ml
of BPE, 50ng/ml of EGF, and 1x PSG. TheHPV-negative cell linesUM-SCC-74A, UM-SCC-5, UM-SCC-11A, andUM-SCC-14A (a gift
from Thomas Carey, University of Michigan, Ann Arbor, MI) were grown in DMEM (GIBCO, cat. #: 11965-092) supplemented with
10% heat-inactivated FBS, 1x PSG, 1x GlutaMAX, and 1xMEM non-essential amino acids (GIBCO, cat. #: 11140050). The additional
HPV-negative cell lines SCC-15 andSCC-25 (a gift fromBenMajor, UNC-Chapel Hill, Chapel Hill, NC) were grown according to ATCC
cell culture conditions. The HPV-positive cells UM-SCC-47, 93-VU-147T, UD-SCC-2, and UPCI:SCC090 (a gift from Randall Kimple,
University of Wisconsin, Madison, WI) were cultured in DMEM media supplemented with 10% FBS, 1x PSG, and 1x GlutaMAX.
METHOD DETAILS
Bioinformatics
Reads from TCGA HNSC RNA-seq were aligned to the human genome using STAR v2.4.2a (Dobin et al., 2013) allowing for 5 mis-
matches and 1080 multi-maps. Reads that did not align to the human genome were aligned to a curated vertebrate virus reference
downloaded from GenBank December 2015, with the addition of HPV16 from the PaVE database using STAR v2.4.2a allowing for 4
mismatches and 52multi-maps. Unspliced and spliced HPV16 early gene transcripts were quantified by counting reads that includede4 Cell Reports 29, 1660–1674.e1–e7, November 12, 2019
the splice junction (nt 226̂ 409) or spanning reads (nt 226/227 and 408/409) and calculating the mean coverage for each sample.
Readswere counted as splicing when their cigar string in the SAMfile included the splice junction, while readswere counted as span-
ning when they started or ended within 50 bp of the splice junction but had a cigar string that indicated that they went into the intron
rather than being spliced. We calculated average coverage by taking each read that was more than 50 bp past the end of the splice
and parsing its cigar string to determine which genomic positions it covers, then calculating the mean of the coverage of that region.
Differentially expressed genes were determined using DESeq2 (Love et al., 2014) and spliced E6*I ratio as the predictor. Gene
expression modules were screened for association with E6*I ratios using theWald statistic from DESeq2. Genes within each module
were stratified by the sign of the statistic and scores calculated for each stratum by summing the statistic for each gene in themodule
and dividing that sum by the square root of the sum of the statistic of the genes in the module. Thus, each module is represented by
two statistics representing the strength of increasing and decreasing gene expression. Permutation tests were performed to char-
acterize the false discovery rate for thresholds of the module scores by shuffling the E6*I ratios and repeating the gene level DESeq2
statistic. This test yielded scores more extreme than 12 or 12 approximately 5 times each out of 100, thus a pathway score more
extreme than 12 or 12 was assigned an empirical q-value of 0.05.
Tamoxifen and 4NQO administration
To conditionally induce GpNLuc or E7iresE6 expression, iLumiFluor or iKH and iKHP animals were intra-lingually injected using a
27-gauge needle with 0.5mg of tamoxifen (Sigma-Aldrich, cat. #: T5648) dissolved in 30ml corn oil (MP Biomedical, cat. #:
901414) either two and/or three times over a five-day period, respectively.
4NQO (4-Nitroquinoline 1-oxide; Sigma, cat. #: N8141) was dissolved in propylene glycol (Sigma, cat. #: 398039) at a concentration
of 5 mg/mL and then further diluted to a final concentration of 10 or 20 mg/ml in sterile ddH2O. Following intra-lingual tamoxifen
administration, animals were allowed a one-week recovery period prior to being administered 4NQO treated water for 8 weeks as
previously described (Vitale-Cross et al., 2009). The 4NQO treated water was changed weekly.
Histological analysis and immunohistochemistry
Tissue harvesting and histological analysis were performed as previously described with minor modification (Herber et al., 1996).
Briefly, all animals showing obvious tumors or other signs of distress were euthanized and subjected to full necropsy. For histological
analysis, all tissues including whole head and/or tumors from LH, KH, iKH, and iKHP animals were fixed in 10% neutral buffered
formalin for approximately 108 hr at room temperature. Following fixation, forehead and left cheek skin and tongues were extracted,
and processed on an ASP6025 automated tissue processor (Leica Biosystems), and embedded in paraffin wax. Blocks were
sectioned at 4-6 mm,mounted on glass slides, and FFPE tissue sections were deparaffinized prior to staining. Hematoxylin and eosin
(H&E) staining was performed using pre-mixed hematoxylin, clarifier, bluing reagent, and eosin (Richard Allan Scientific). Immuno-
histochemistry was performed on the Discovery Ultra (Ventana Medical Systems) using manufacturers reagents on 4mm sections.
Briefly, anti-MouseCD8a (eBioscience, cat. #: 14-0808) was prepared usingDiscovery PSSDiluent (cat. #: 760-212). Antigen retrieval
was performed using Ventana’s CC1 (pH 8.5) for 64 min at 90C. The slides were given a hydrogen peroxide block for 8 min at room
temperature and then incubated in the primary antibody diluent (1:100) for 1 hr at room temperature, followed by anti-Rat HRP sec-
ondary antibody (Ventana Omap OmniMap, cat. #: 760-4457) for 32 min at room temperature. The slides were then treated with DAB
and counterstained with Hematoxylin II for 12 min and then Bluing Reagent for 4 min.
Alternatively, the anti-Mouse/Rat Foxp3 (eBioscience, cat. #: 14-5773) was prepared using Discovery Ab Diluent (Ventana Omap
OmniMap, cat. #: 760-108). Antigen retrieval was performed using Ventana’s CC1 (pH 8.5), for 24min at 100C and then blockedwith
a protein block for 1 hr at room temperature. The slides were given a hydrogen peroxide block for 8min at room temperature and then
incubated in the primary antibody diluent (1:50) for 2 hr at room temperature, followed by the anti-Rat HRP secondary antibody for
32 min at room temperature. The slides were treated with Discovery Purple for 100 min. For each genotype, R 3 animals from any
given time point were examined and multiple similar grade tumors scored.
Immunofluorescence
Back skin or oral tissues (tongue) from p45 animals were fixed in 4%Paraformaldehyde for 0.5-1 hr followed by PBSwashes. Tissues
were incubated in 15% and 30% sucrose gradient at 4C prior to embedding in O.C.T compound (Tissue Tek, cat. #: 4583) without
prior fixation. Tissues were sectioned to 8mm on a Leica CM1950 cryostat using DB80LX blades (cat. #: 14035843496), mounted on
SuperFrost Plus glass slides (Fisher Scientific, cat. #: 12-550-15), and dried 10 min at 37C. Fresh frozen tissue from p0 mice and
fixed p45 skin sections were fixed for 5min with 4%PFA, washedwith PBS, and blocked in a gelatin block (5% normal donkey serum
(Jackson Immunoresearch, cat. #: 017-000-121), 3%BSA, 8%gelatin (Sigma cat. #: G7765), and 0.05%Triton X-100 in PBS) for 1 hr.
Sections were stained with primary antibodies diluted in gelatin block and incubated overnight at 4C, washed three times with PBS,
incubated 2 hr with secondary antibodies at room temperature, counterstained with DAPI for 5 min at room temperature, and
mounted in ProLong Gold (Invitrogen, cat. #: P36930). Tissues were stained with primary and secondary antibodies (Table S6)
and images acquired using LAS AF software on a Leica TCS SPE-II 4 laser confocal system on a DM5500microscope with ACS Apo-
chromat 20 3 /0.60 multi-immersion, ACS Apochromat 40 3 /1.15 oil, and ACS Apochromat 63 3 /1.30 oil objectives.Cell Reports 29, 1660–1674.e1–e7, November 12, 2019 e5
In vivo BLI
Bioluminescent-fluorescent BRET signal was measured non-invasively as previously described (Schaub et al., 2015) with minor
modification. Briefly, animals were injected tail-vein with 250 mM (1:20 dilution, 500 mg/kg) Nano-Glo Luciferase Assay Substrate
(Promega, cat. #: N1138) in sterile PBS. Isoflurane-anesthetized animals were then imaged using an IVIS Kinetic (PerkinElmer)
5 min after injection. Images were captured with open filter and acquisition times of 60 s or less at the indicated settings. Data
were analyzed using the Living Image software.
Plasmids
The pBigT and pRosa26-PA (Srinivas et al., 2001) constructs (Addgene plasmid #21270 and #21271, respectively) were gifts from
Frank Costantini, MIGR1 (Pear et al., 1998) (Addgene plasmid #27490) was a gift from Warren Pear, and the pRetroX-Tight-
MCS_PGK-GpNLuc construct (Addgene plasmid #70185) containing the LumiFluor optical reporter was previously described
(Schaub et al., 2015).
PCR and qPCR
Recombination was assessed by lysing cells (100 mM NaCl, 10 mM Tris pH 8, 25mM EDTA pH 8, 0.5% SDS, and 50 mg/ml
Proteinase K) and extracting genomic DNA using phenol-chloroform and ethanol precipitation. Briefly, MEFs from founders and es-
tablished lines were tested by transducing cells with Adeno-Cre virus (MOI = 20) and analyzing the recombined allele from the
Rosa26-LSL-E7iresE6 mice by PCR (PrimeSTAR GXL DNA polymerase - Takara Bio USA, cat. #: R050A) using pBigT-E7iresE6 as
a control with the following primers (Table S7) and cycling conditions: 95 C for 3 min followed by 98 C for 10 s, 55 C for 15 s
and 68 C for 40 s for 34 cycles and 5 min for 68C.
For cell lines, gene expression wasmeasured by extracting RNA using a Nucleospin RNA kit (Machery-Nagel, cat #: 740955) as per
the manufacturer’s recommendations. cDNA was made from 0.65 mg (HNSCC and NOKs) or 1 mg (MEFs) of RNA using iScript cDNA
synthesis kit (Bio-Rad, cat. #: 170-8890). For tissues, gene expression was measured by extracting RNA from tissues snap frozen in
liquid nitrogen and homogenized with liquid nitrogen using mortar and pestle. RNA was then prepared using NucleoZOL (Macherey-
Nagel, cat. #: 740404.200) in accordance with the manufacturer’s instructions. cDNA was made from 0.5-1 mg of RNA using
SuperScript IV Reverse Transcriptase (Invitrogen, cat. #: 18090050) with dNTPs (NEB, cat. #: N0446S), RNase inhibitor (Applied
Biosystems, cat. #: N808-0119), and 50 mM oligo d(T)20 primers (Invitrogen, cat. #: 100023441). HPV16 E6 and E7 copy number
was determined by establishing standard curves with 100 to 1x106 copies of the pBigT-E7iresE6 construct. Relative gene expression
of E6, E7, E6/TP53, and E7/E2F1 targets was determined using the 2DDCt method and normalized using human and mouse RPL23.
Expression in HNSCCcell lines relative to NOKswas calculated using theDCT ofOKF4-TERT1. qPCRwas performed using FastStart
Universal SYBR Green Master (Rox) Mix (Roche, cat. #: 04913850001) with 1/20 (tissue) or 1/40 (cells) volume of the cDNA iScript
reaction, and 0.25 mM of primers (Table S7).
For basal keratinocytes, tissues were treated with Dispase overnight to enable separation of the epidermis from the dermis. The
epidermal layer was then further processed with Typsin and passed through a 70 mm cell strainer, snap frozen in liquid nitrogen, and
RNA was then isolated using QIAGEN RNeasy (QIAGEN, cat. #: 74104) in accordance with the manufacturer’s instructions. cDNA
was made from 250 ng of RNA using iScript (Biorad, cat#1708891) Reverse Transcriptase, diluted 1:5 in ddH2O, and qPCR per-
formed using iTaq Universal SYBR green supermix (BioRad, cat. #: 1725121).
Western blotting
Whole cell lysates were prepared in buffer containing 250 mM NaCl, 50 mM Tris (pH 7.4), 50 mM NaF, 0.1 mM NaVO4, 5 mM EDTA,
and 0.1% Triton X-100 supplemented with protease inhibitors (cOmplete, EDTA-free Protease Inhibitor Cocktail - Roche, cat. #:
04693132001) and phosphatase inhibitors (phosphoSTOP, - Roche, cat. #: 10917400). Lysates (30-50 mg) were loaded onto
mini-16% tris-glycine polyacrylamide gels and proteins separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), then transferred to a 0.2 mm nitrocellulose membrane (GE Healthcare Life Sciences, cat. #: 10600011) using a Bio-Rad
Transblot Turbo System set at 1.0 Amps (constant), 25 V, and run for 22min.Membraneswere blocked for 1 hr at room temperature in
TBS-T + 5% milk and then incubated over night at 4C with primary antibodies (Table S6): HPV16 E6 (1:1000-1:2000 - Gene Tex,
cat. #: GTX132686) or HPV16 E7 (1:1000 - Gene Tex, cat. #: GTX133411) diluted in TBS-T + 3% milk. Following primary antibody
incubation, membranes were washed and probedwith Horseradish peroxidase (HRP)-conjugated goat anti-mouse (1:2500 - Thermo
Fisher, cat. #: 31432) or donkey anti-rabbit (1:2500 - Thermo Fisher, cat. #: 31458) secondary antibodies for 1-2 hr at room temper-
ature. Blots were imaged using Clarity ECL (Bio-Rad, cat. #: 170-5060) and ImageQuant LHS4000 (GE). Data are normalized using
rabbit anti-Gapdh for MEFs (1:2000 - Santa Cruz, cat. #: sc-25778) or mouse anti-b-actin (1:5000 - Sigma Life Sciences, cat. #:
A3854). Densitometry analysis was performed using ImageQuant TL software (GE).e6 Cell Reports 29, 1660–1674.e1–e7, November 12, 2019
QUANTIFICATION AND STATISTICAL ANALYSIS
Each in vivo and in vitro experiment was performed in triplicate and repeated at least three times. All statistical tests were executed
using GraphPad Prism software or the statistical software R (version 3.1.2). Differences between variables were assessed by 2-tailed
Student’s t test or 2-way ANOVA with Bonferroni’s post hoc tests, where appropriate. Data are expressed as mean ± SEM P values
less than 0.05 were considered statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001).
DATA AND CODE AVAILABILITY
This study did not generate any unique datasets or code.Cell Reports 29, 1660–1674.e1–e7, November 12, 2019 e7
